TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

RESOLUTIONS PASSED AT THE 7TH BOARD MEETING FOR FY2026

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 3 August 2026, the Company issued a notice to its directors (the "**Directors**") convening the 7th Board meeting for the financial year ending 31 December 2026 ("**FY2026**"). The meeting was duly convened on 13 August 2026 via a combination of a physical meeting and teleconference and was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were duly passed at the meeting:

1. That the full text and summary of the half-yearly financial statement for FY2026, prepared in accordance with the accounting standards of the People's Republic of China, and the interim financial report for FY2026, prepared in accordance with the International Financial Reporting Standards, be approved.

   To the best of the knowledge of the Directors and management of the Company, there is no other information that would cause the contents of the aforesaid reports to be false or misleading.

   Please refer to the Company's separate announcement on its second quarter and/or half-yearly results released on the same date as this announcement for further details.

2. That the half-yearly "Report on the Deposit of Proceeds and the Use of Proceeds (募集资金存放与实际使用情况的专项报告)" for FY2026 be approved.

   Please refer to the Company's separate announcement entitled "*Update on the Deposit of Net Proceeds and the Use of New Proceeds*" released on the same date as this announcement for further details.

3. That the Company's "Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. (关于对天津医药集团财务有限公司的风险持续评估报告)" be approved.

   Please refer to the Company's separate announcement entitled "*Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司)*" released on the same date as this announcement for further details.

4. That the proposed amendments to the Articles of Association of the Company and the application for changes in the industrial and commercial registration be approved.

Please refer to the Company's separate announcement entitled "*Proposed Amendments to the Articles of Association of the Company and Application for Changes in the Industrial and Commercial Registration*" released on the same date as this announcement for further details.

Resolution 4 above will be tabled for shareholders' approval at a general meeting of the Company to be convened in due course.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
14 August 2026